ArticleScientific reports2021
Population pharmacokinetic model of cefazolin in total hip arthroplasty.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 19 citations in OpenAlex.
- Protein Binding of Cefazolin is Not Saturated in Human Synovial Fluid After Single-Dose Perioperative Antibiotic Prophylaxis.European journal of drug metabolism and pharmacokinetics · 2026Article
- Cefazolin surgical prophylaxis in obesity: a body composition-driven population pharmacokinetic approach.Antimicrobial agents and chemotherapy · 2026Article
- Pharmacokinetics of cefazolin in bariatric surgery patients: a preoperative perspective.The Journal of antimicrobial chemotherapy · 2026Observational
- β-Lactam Antibiotics in Obese Adults: A Review of Population Pharmacokinetic Analyses.Clinical pharmacokinetics · 2026Review
- The Cefazolin Inoculum Effect: An Underappreciated Factor in MSSA Treatment Strategies.Infectious diseases and therapy · 2026Review
- Cerebrospinal Pharmacokinetic Modeling and Pharmacodynamic Simulation of High-Dose Cefazolin for Meningitis Caused by Methicillin-SusceptibleAntibiotics (Basel, Switzerland) · 2025Article
- The effect of intraoperative excessive bleeding on the pharmacokinetics of ampicillin and sulbactam in recipients of living donor liver transplantation in Japan.JAC-antimicrobial resistance · 2025Article
- Systemic antibiotic prophylaxis in arthroplasty - a narrative review of how many doses are optimal.EFORT open reviews · 2024Review
- Dose optimization of cefazolin in South African children undergoing cardiac surgery with cardiopulmonary bypass.CPT: pharmacometrics & systems pharmacology · 2024Article
- Heparin Dosing Regimen Optimization in Veno-Arterial Extracorporeal Membrane Oxygenation: A Pharmacokinetic Analysis.Pharmaceutics · 2024Article
- Morphomics-informed population pharmacokinetic and physiologically-based pharmacokinetic modeling to optimize cefazolin surgical prophylaxis.Pharmacotherapy · 2024Article
- Effective Antimicrobial Prophylaxis in Surgery: The Relevance and Role of Pharmacokinetics-Pharmacodynamics.Antibiotics (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cefazolin is an antibiotic recommended for infection prevention in total hip arthroplasty (THA). However, the dosing regimen necessary to achieve therapeutic concentrations in obese patients remains unclear. The aim of this study was to conduct a population analysis of cefazolin pharmacokinetics (PK) and assess whether cefazolin administration should be weight adapted in THA. Adult patients undergoing THA surgery received an injection of 2000 mg of cefazolin, doubled in the case of BMI > 35 kg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.